Ramsay Generale de Sante (GDS) AI Stock Analysis

• Market Cap: €1.10B
• Dividend Yield: N/A
• Average Volume (3M): 237.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.07
• Revenue Growth: 4.70%
• EPS Growth: -0.33%
• Country: FR
• Employees: 34,218
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.10
• Shares Outstanding: 110,389,690
• 10 Day Avg. Volume: 250
• 30 Day Avg. Volume: 237
• PEG Ratio: 0.00
• Price to Book (P/B): 1.06
• Price to Sales (P/S): 0.23
• P/FCF Ratio: 2.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €10.00
• Price Target Upside: 0.20% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: €10.00 ▲(0.20% Upside)

The overall stock score is primarily influenced by financial performance, which shows stable revenue growth and strong cash flow but is hindered by profitability challenges and high leverage. Technical analysis indicates a bearish trend, and valuation metrics highlight financial losses and lack of dividends.

Ramsay Generale de Sante Business Overview & Revenue Model

Company Description

Ramsay Générale de Santé SA operates hospitals in France. Its hospitals offer a range of services in the areas of anesthesia, oncology, cardiology, dermatology, gastroenterology, gynecology, maternity, nephrology, neurosurgery, obesity, ophthalmology, orthopedics, stomatology, pneumonology, psychiatry, radiology, and urology, as well as thoracic, vascular, and endovascular surgeries. The company was formerly known as Générale de Santé SA and changed its name to Ramsay Générale de Santé SA in December 2015. Ramsay Générale de Santé SA was founded in 1987 and is based in Paris, France. Ramsay Générale de Santé SA operates as a subsidiary of Ramsay Health Care Limited.

How the Company Makes Money

Ramsay Generale de Sante generates revenue primarily through the provision of medical and healthcare services across its network of hospitals and clinics. The company charges patients or their insurance providers for treatments, procedures, and consultations. Additionally, GDS benefits from partnerships with public health agencies and contracts with private health insurers, ensuring a steady stream of income. Ancillary services such as diagnostics, laboratory tests, and pharmacy sales also contribute to the company's revenue. GDS's focus on efficiency and high-quality service delivery helps maintain its profitability in the competitive healthcare sector.

Ramsay Generale de Sante Financial Statement Overview

Summary

Ramsay Generale de Sante shows stable revenue growth and strong cash flow generation, which are positive indicators. However, challenges with profitability and high leverage could impact financial stability.

Income Statement

Ramsay Generale de Sante shows a modest revenue growth rate of 1.91% in the most recent year, indicating stability in revenue generation. However, the company faces challenges with profitability, as evidenced by a negative net profit margin. The gross profit margin remains strong, suggesting efficient cost management, but the negative net income highlights issues in controlling other expenses or financial costs.

Balance Sheet

The company's balance sheet reflects a high debt-to-equity ratio, indicating significant leverage which could pose financial risks. The return on equity is negative, driven by the net losses, which is a concern for investors. However, the equity ratio is reasonable, suggesting a balanced asset structure.

Cash Flow

Ramsay Generale de Sante demonstrates strong cash flow management with a significant free cash flow growth rate of 25.21%. The operating cash flow to net income ratio is robust, indicating effective cash generation relative to accounting profits. However, the free cash flow to net income ratio suggests that cash flow is not fully translating into profitability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.24B	5.24B	5.01B	4.70B	4.30B	4.02B
Gross Profit	1.21B	4.08B	3.94B	3.72B	3.41B	3.20B
EBITDA	474.20M	599.70M	591.30M	656.30M	691.00M	604.00M
Net Income	-54.10M	-54.10M	-53.90M	49.40M	118.40M	65.00M
Balance Sheet
Total Assets	6.84B	6.84B	6.90B	6.96B	6.79B	6.68B
Cash, Cash Equivalents and Short-Term Investments	384.00M	384.00M	381.30M	362.90M	143.50M	620.00M
Total Debt	4.08B	4.08B	4.06B	4.15B	3.97B	3.85B
Total Liabilities	5.66B	5.66B	5.67B	5.68B	5.55B	5.58B
Stockholders Equity	1.15B	1.15B	1.19B	1.25B	1.21B	1.07B
Cash Flow
Free Cash Flow	498.30M	550.90M	418.30M	426.70M	68.90M	475.90M
Operating Cash Flow	641.10M	693.70M	586.80M	598.90M	262.50M	652.30M
Investing Cash Flow	-179.30M	-138.40M	-180.50M	-175.40M	-471.10M	-181.40M
Financing Cash Flow	-589.85M	-550.20M	-401.50M	-197.10M	-264.20M	-390.60M

Ramsay Generale de Sante Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GDS, the sentiment is Neutral. The current price of 9.98 is above the 20-day moving average (MA) of 9.89, below the 50-day MA of 10.09, and below the 200-day MA of 10.50, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 53.50 is Neutral, neither overbought nor oversold. The STOCH value of 56.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:GDS.

Ramsay Generale de Sante Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VETO	72 Outperform	914.16M	14.98	10.19%	1.15%	-0.95%	27.67%
LNA	65 Neutral	259.46M	12.73	6.95%	5.22%	13.30%	-15.12%
VIRP	63 Neutral	2.63B	19.55	13.93%	0.46%	6.97%	-5.59%
CLARI	60 Neutral	1.54B	-33.39	-1.49%	―	1.98%	85.87%
GDS	48 Neutral	€1.10B	―	-4.36%	―	4.70%	-0.33%
EMEIS	40 Neutral	2.19B	-5.08	-23.89%	―	8.43%	-102.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%